Kevin Grogan

AstraZeneca and Amgen's thymic stromal lymphopoietin inhibitor, which is already approved for severe asthma and chronic rhinosinusitis with nasal polyps, is heading to the regulators after hitting its primary goals in an eosinophilic esophagitis trial.

The firm has revealed the extent of the win seen in the ACACIA-HCM study in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, a setting where Bristol Myers Squibb's rival cardiac myosin inhibitor Camzyos failed.

The Italian firm is hoping for a first Phase III read-out for evenamide in the first quarter of next year.

Deal Snapshot: The UK major is linking up with the prolific Chinese R&D company to license an experimental antibody-drug conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors.

Deal Snapshot: The Italy-headquartered firm is linking up with the Chinese metabolic disease specialist and has bagged the rights in Europe to bofanglutide, a fortnightly injection for weight management.

The megablockbuster helped 40% of children reduce BMI below the obesity threshold at 68 weeks, compared with 0% for placebo, in the STEP Young trial.

It is the second major clinical setback in a week for the Swiss firm after pelacarsen disappointed in a Phase III cardiovascular outcomes study.

The late-stage failures within days of pelacarsen and del-desiran ‘will likely raise questions again about Novartis's due diligence and BD approach,' analysts at Jefferies have claimed.

The timelines for the MO-TRANS trial of the sphingosine 1 phosphate receptor modulator have been pushed back as the number of patients enrolled increased significantly but that ‘puts us in the strongest position to generate robust Phase III data,' CEO Florent Gros tells Scrip.

The FDA could soon make the IL-6 inhibitor the first approved drug for myelin oligodendrocyte glycoprotein antibody-associated disease and Enspryng may have three approvals by the end of January.